Net Income (Loss) Attributable to Parent in USD of LEXICON PHARMACEUTICALS, INC. from Q2 2010 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
LEXICON PHARMACEUTICALS, INC. quarterly/annual Net Income (Loss) Attributable to Parent history and change rate from Q2 2010 to Q3 2025.
  • LEXICON PHARMACEUTICALS, INC. Net Income (Loss) Attributable to Parent for the quarter ending 30 Sep 2025 was -$12.8M, a 80.3% increase year-over-year.
  • LEXICON PHARMACEUTICALS, INC. Net Income (Loss) Attributable to Parent for the twelve months ending 30 Sep 2025 was -$68.6M, a 68.3% increase year-over-year.
  • LEXICON PHARMACEUTICALS, INC. annual Net Income (Loss) Attributable to Parent for 2024 was -$200M, a 13.1% decline from 2023.
  • LEXICON PHARMACEUTICALS, INC. annual Net Income (Loss) Attributable to Parent for 2023 was -$177M, a 73.7% decline from 2022.
  • LEXICON PHARMACEUTICALS, INC. annual Net Income (Loss) Attributable to Parent for 2022 was -$102M, a 16.2% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

LEXICON PHARMACEUTICALS, INC. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$68.6M -$12.8M +$52M +80.3% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025
Q2 2025 -$121M $3.25M +$56.7M 01 Apr 2025 30 Jun 2025 10-Q 06 Nov 2025
Q1 2025 -$177M -$25.3M +$23.1M +47.7% 01 Jan 2025 31 Mar 2025 10-Q 06 Nov 2025
Q4 2024 -$200M -$33.8M +$16M +32.1% 01 Oct 2024 31 Dec 2024 10-K 07 Mar 2025
Q3 2024 -$216M -$64.8M -$14.3M -28.3% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025
Q2 2024 -$202M -$53.4M -$8.53M -19% 01 Apr 2024 30 Jun 2024 10-Q 06 Nov 2025
Q1 2024 -$194M -$48.4M -$16.5M -51.6% 01 Jan 2024 31 Mar 2024 10-Q 06 Nov 2025
Q4 2023 -$177M -$49.8M -$19.3M -63.2% 01 Oct 2023 31 Dec 2023 10-K 07 Mar 2025
Q3 2023 -$158M -$50.5M -$27.1M -116% 01 Jul 2023 30 Sep 2023 10-Q 13 Nov 2024
Q2 2023 -$131M -$44.9M -$20.3M -82.6% 01 Apr 2023 30 Jun 2023 10-Q 13 Nov 2024
Q1 2023 -$110M -$31.9M -$8.46M -36% 01 Jan 2023 31 Mar 2023 10-Q 13 Nov 2024
Q4 2022 -$102M -$30.5M -$4.88M -19.1% 01 Oct 2022 31 Dec 2022 10-K 07 Mar 2025
Q3 2022 -$97.1M -$23.4M -$265K -1.15% 01 Jul 2022 30 Sep 2022 10-Q 08 Nov 2023
Q2 2022 -$96.8M -$24.6M -$6.52M -36.1% 01 Apr 2022 30 Jun 2022 10-Q 08 Nov 2023
Q1 2022 -$90.3M -$23.5M -$2.52M -12% 01 Jan 2022 31 Mar 2022 10-Q 08 Nov 2023
Q4 2021 -$87.8M -$25.6M -$20.1M -366% 01 Oct 2021 31 Dec 2021 10-K 25 Mar 2024
Q3 2021 -$67.6M -$23.1M -$106M -128% 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022
Q2 2021 $38.1M -$18.1M +$51M +73.8% 01 Apr 2021 30 Jun 2021 10-Q 03 Aug 2022
Q1 2021 -$12.9M -$21M +$45.7M +68.5% 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022
Q4 2020 -$58.6M -$5.5M +$45.6M +89.3% 01 Oct 2020 31 Dec 2020 10-K 03 Mar 2023
Q3 2020 -$104M $82.6M -$143M -63.5% 01 Jul 2020 30 Sep 2020 10-Q 09 Nov 2021
Q2 2020 $39.3M -$69.1M -$46.1M -200% 01 Apr 2020 30 Jun 2020 10-Q 06 Aug 2021
Q1 2020 $85.3M -$66.6M -$44.8M -206% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021
Q4 2019 $130M -$51.1M -$34.4M -205% 01 Oct 2019 31 Dec 2019 10-K 12 Mar 2020
Q3 2019 $164M $226M +$253M 01 Jul 2019 30 Sep 2019 10-Q 30 Oct 2020
Q2 2019 -$89M -$23M +$11.5M +33.4% 01 Apr 2019 30 Jun 2019 10-Q 29 Jul 2020
Q1 2019 -$101M -$21.8M +$20M +47.9% 01 Jan 2019 31 Mar 2019 10-Q 27 Apr 2020
Q4 2018 -$121M -$16.8M +$9.83M +36.9% 01 Oct 2018 31 Dec 2018 10-K 12 Mar 2020
Q3 2018 -$130M -$27.4M +$2.41M +8.1% 01 Jul 2018 30 Sep 2018 10-K 12 Mar 2020
Q2 2018 -$133M -$34.5M +$108K +0.31% 01 Apr 2018 30 Jun 2018 10-K 12 Mar 2020
Q1 2018 -$133M -$41.8M -$9.9M -31% 01 Jan 2018 31 Mar 2018 10-K 12 Mar 2020
Q4 2017 -$123M -$26.6M +$5.81M +17.9% 01 Oct 2017 31 Dec 2017 10-K 15 Mar 2019
Q3 2017 -$129M -$29.8M +$6.21M +17.2% 01 Jul 2017 30 Sep 2017 10-K 15 Mar 2019
Q2 2017 -$135M -$34.7M +$3.46M +9.07% 01 Apr 2017 30 Jun 2017 10-K 15 Mar 2019
Q1 2017 -$138M -$31.9M +$2.97M +8.5% 01 Jan 2017 31 Mar 2017 10-K 15 Mar 2019
Q4 2016 -$141M -$32.4M -$119M -137% 01 Oct 2016 31 Dec 2016 10-K 01 Mar 2018
Q3 2016 -$22.3M -$36M -$733K -2.08% 01 Jul 2016 30 Sep 2016 10-K 01 Mar 2018
Q2 2016 -$21.5M -$38.1M -$10M -35.8% 01 Apr 2016 30 Jun 2016 10-K 01 Mar 2018
Q1 2016 -$11.5M -$34.9M -$6.81M -24.2% 01 Jan 2016 31 Mar 2016 10-K 01 Mar 2018
Q4 2015 -$4.68M $86.8M +$89.7M 01 Oct 2015 31 Dec 2015 10-K 01 Mar 2018
Q3 2015 -$94.4M -$35.3M +$5.22M +12.9% 01 Jul 2015 30 Sep 2015 10-Q 07 Nov 2016
Q2 2015 -$99.6M -$28.1M -$2.05M -7.86% 01 Apr 2015 30 Jun 2015 10-Q 04 Aug 2016
Q1 2015 -$97.5M -$28.1M +$2.76M +8.95% 01 Jan 2015 31 Mar 2015 10-Q 05 May 2016
Q4 2014 -$100M -$2.93M +$14.5M +83.2% 01 Oct 2014 31 Dec 2014 10-K 12 Mar 2015
Q3 2014 -$115M -$40.5M -$8.84M -27.9% 01 Jul 2014 30 Sep 2014 10-Q 09 Nov 2015
Q2 2014 -$106M -$26M +$3.05M +10.5% 01 Apr 2014 30 Jun 2014 10-Q 07 Aug 2015
Q1 2014 -$109M -$30.8M -$4.86M -18.7% 01 Jan 2014 31 Mar 2014 10-Q 05 May 2015
Q4 2013 -$104M -$17.4M +$7.46M +30% 01 Oct 2013 31 Dec 2013 10-K 12 Mar 2015
Q3 2013 -$112M -$31.7M -$2.12M -7.17% 01 Jul 2013 30 Sep 2013 10-K 12 Mar 2015
Q2 2013 -$109M -$29.1M -$3.15M -12.1% 01 Apr 2013 30 Jun 2013 10-K 12 Mar 2015
Q1 2013 -$106M -$26M +$3.89M +13% 01 Jan 2013 31 Mar 2013 10-K 12 Mar 2015
Q4 2012 -$110M -$24.9M +$8.97M +26.5% 01 Oct 2012 31 Dec 2012 10-K 07 Mar 2014
Q3 2012 -$119M -$29.5M -$3.44M -13.2% 01 Jul 2012 30 Sep 2012 10-K 07 Mar 2014
Q2 2012 -$116M -$25.9M +$707K +2.65% 01 Apr 2012 30 Jun 2012 10-K 07 Mar 2014
Q1 2012 -$116M -$29.9M -$239K -0.81% 01 Jan 2012 31 Mar 2012 10-K 07 Mar 2014
Q4 2011 -$116M -$33.8M 01 Oct 2011 31 Dec 2011 10-K 11 Mar 2013
Q3 2011 -$26.1M +$1.41M +5.13% 01 Jul 2011 30 Sep 2011 10-K 11 Mar 2013
Q2 2011 -$26.6M -$1.45M -5.74% 01 Apr 2011 30 Jun 2011 10-K 11 Mar 2013
Q1 2011 -$29.6M 01 Jan 2011 31 Mar 2011 10-K 11 Mar 2013
Q3 2010 -$27.5M 01 Jul 2010 30 Sep 2010 10-Q 01 Nov 2011
Q2 2010 -$25.2M 01 Apr 2010 30 Jun 2010 10-Q 09 Aug 2011

LEXICON PHARMACEUTICALS, INC. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$200M -$23.3M -13.1% 01 Jan 2024 31 Dec 2024 10-K 07 Mar 2025
2023 -$177M -$75.2M -73.7% 01 Jan 2023 31 Dec 2023 10-K 07 Mar 2025
2022 -$102M -$14.2M -16.2% 01 Jan 2022 31 Dec 2022 10-K 07 Mar 2025
2021 -$87.8M -$29.2M -49.8% 01 Jan 2021 31 Dec 2021 10-K 25 Mar 2024
2020 -$58.6M -$189M -145% 01 Jan 2020 31 Dec 2020 10-K 03 Mar 2023
2019 $130M +$251M 01 Jan 2019 31 Dec 2019 10-K 10 Mar 2022
2018 -$121M +$2.45M +1.99% 01 Jan 2018 31 Dec 2018 10-K 12 Mar 2021
2017 -$123M +$8.45M +6.43% 01 Jan 2017 31 Dec 2017 10-K 12 Mar 2020
2016 -$131M -$127M -2707% 01 Jan 2016 31 Dec 2016 10-K 15 Mar 2019
2015 -$4.68M +$95.6M +95.3% 01 Jan 2015 31 Dec 2015 10-K 01 Mar 2018
2014 -$100M +$3.83M +3.68% 01 Jan 2014 31 Dec 2014 10-K 06 Mar 2017
2013 -$104M +$6.09M +5.52% 01 Jan 2013 31 Dec 2013 10-K 11 Mar 2016
2012 -$110M +$6M +5.17% 01 Jan 2012 31 Dec 2012 10-K 12 Mar 2015
2011 -$116M -$14.4M -14.2% 01 Jan 2011 31 Dec 2011 10-K 07 Mar 2014
2010 -$102M 01 Jan 2010 31 Dec 2010 10-K 11 Mar 2013
* An asterisk sign (*) next to the value indicates that the value is likely invalid.